Literature DB >> 11471106

In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages.

M Grinsell1, L C Weinhold, J E Cutler, Y Han, T R Kozel.   

Abstract

Cryptococcus neoformans produces a life-threatening meningitis in patients who are immunocompromised by AIDS. A striking feature of cryptococcosis in AIDS is high serum levels of the major capsular polysaccharide, glucuronoxylomannan (GXM). Soluble GXM has numerous biologic activities that may contribute to the pathogenesis of infection. The objective of the study was to further understand in vivo processing of GXM. Mice were injected intravenously with GXM, and the tissue distribution was determined. A macrophage suicide technique that used liposome-encapsulated dichloromethylene diphosphonate determined the role of macrophages. GXM was cleared from serum with a half-life of 24-48 h but was retained for an indefinite period in tissues rich in cells of the mononuclear phagocyte system. Ablation of macrophages decreased GXM in the liver and spleen and increased serum GXM. The results identify a key role for macrophages in the clearance of GXM from serum and identify macrophages as a long-term reservoir for storage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11471106     DOI: 10.1086/322787

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Capsular Material of Cryptococcus neoformans: Virulence and Much More.

Authors:  A Vecchiarelli; C Monari
Journal:  Mycopathologia       Date:  2012-02-08       Impact factor: 2.574

2.  Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid.

Authors:  Taseera Kabanda; Mark J Siedner; Jeffrey D Klausner; Conrad Muzoora; David R Boulware
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079

3.  Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.

Authors:  Zong Liang Chang; Dale Netski; Peter Thorkildson; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

4.  Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo.

Authors:  Lauren E Yauch; Michael K Mansour; Stuart M Levitz
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Long-term maintenance of polysaccharide-specific antibodies by IgM-secreting cells.

Authors:  Jeremy B Foote; Tamer I Mahmoud; Andre M Vale; John F Kearney
Journal:  J Immunol       Date:  2011-11-23       Impact factor: 5.422

6.  Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.

Authors:  Thomas R Kozel; Stuart M Levitz; Françoise Dromer; Marcellene A Gates; Peter Thorkildson; Guilhem Janbon
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

7.  Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo.

Authors:  Lauren E Yauch; Michael K Mansour; Shmuel Shoham; James B Rottman; Stuart M Levitz
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  Isolation and purification of antigenic components of Cryptococcus.

Authors:  Karen L Wozniak; Stuart M Levitz
Journal:  Methods Mol Biol       Date:  2009

9.  Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.

Authors:  Suzanne Brandt; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

10.  Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan.

Authors:  Kausik Datta; Andrew Lees; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2008-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.